Fulcrum Therapeutics Stock Options
| FULC Stock | USD 3.15 0.13 4.30% |
Fulcrum Therapeutics' latest option contracts expiring on June 20th 2025 are carrying combined implied volatility of 1.49 with a put-to-call open interest ratio of 0.04 over 18 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on June 20th 2025.
Open Interest Against June 20th 2025 Option Contracts
2025-06-20
The chart above shows Fulcrum Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Fulcrum Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Fulcrum Therapeutics' option, there is no secondary market available for investors to trade.
In The Money vs. Out of Money Option Contracts on Fulcrum Therapeutics
Analyzing Fulcrum Therapeutics' in-the-money options over time can help investors to take a profitable long position in Fulcrum Therapeutics regardless of its overall volatility. This is especially true when Fulcrum Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Fulcrum Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Fulcrum Therapeutics' stock while costing only a fraction of its price.
Fulcrum Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of Fulcrum Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Fulcrum stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Fulcrum Therapeutics' stock price goes up or down, the stock options follow.
At present, Fulcrum Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Common Stock is expected to grow to about 74.9 K, whereas Total Stockholder Equity is forecasted to decline to about 157.9 M. Fulcrum Therapeutics In The Money Call Balance
When Fulcrum Therapeutics' strike price is surpassing the current stock price, the option contract against Fulcrum Therapeutics stock is said to be in the money. When it comes to buying Fulcrum Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Fulcrum Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Fulcrum Current Options Market Mood
Fulcrum Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Fulcrum Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Fulcrum Therapeutics' options investors are not very successful. Fulcrum Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Fulcrum contract
Base on the Rule 16, the options market is currently suggesting that Fulcrum Therapeutics will have an average daily up or down price movement of about 0.0931% per day over the life of the 2025-06-20 option contract. With Fulcrum Therapeutics trading at USD 3.15, that is roughly USD 0.002933. If you think that the market is fully incorporating Fulcrum Therapeutics' daily price movement you should consider buying Fulcrum Therapeutics options at the current volatility level of 1.49%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Fulcrum |
Purchasing Fulcrum Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Fulcrum calls. Remember, the seller must deliver Fulcrum Therapeutics stock to the call owner when a call is exercised.
Fulcrum Therapeutics Option Chain
When Fulcrum Therapeutics' strike price is surpassing the current stock price, the option contract against Fulcrum Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Fulcrum Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Fulcrum. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Fulcrum. It also shows strike prices and maturity days for a Fulcrum Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | FULC250620C00010000 | 15 | 10.0 | 0.0 - 0.4 | 0.15 | Out |
Call | FULC250620C00008000 | 1 | 8.0 | 0.0 - 0.45 | 0.15 | Out |
Call | FULC250620C00007000 | 0 | 7.0 | 0.0 - 0.45 | 0.45 | |
Call | FULC250620C00006000 | 86 | 6.0 | 0.0 - 0.45 | 0.45 | Out |
Call | FULC250620C00005000 | 258 | 5.0 | 0.0 - 0.3 | 0.27 | Out |
Call | FULC250620C00004000 | 97 | 4.0 | 0.0 - 0.6 | 0.25 | Out |
Call | FULC250620C00003000 | 45 | 3.0 | 0.55 - 0.75 | 1.35 | In |
Call | FULC250620C00002000 | 3 | 2.0 | 1.15 - 1.35 | 1.27 | In |
Call | FULC250620C00001000 | 0 | 1.0 | 0.1 - 4.2 | 0.1 | In |
Put | FULC250620P00010000 | 0 | 10.0 | 6.9 - 7.1 | 6.9 | In |
Put | FULC250620P00008000 | 0 | 8.0 | 4.8 - 6.3 | 4.8 | In |
Put | FULC250620P00007000 | 0 | 7.0 | 3.3 - 4.1 | 3.3 | In |
Put | FULC250620P00006000 | 0 | 6.0 | 2.7 - 3.2 | 2.7 | In |
Put | FULC250620P00005000 | 10 | 5.0 | 1.9 - 2.3 | 1.6 | In |
Put | FULC250620P00004000 | 6 | 4.0 | 1.05 - 1.5 | 1.15 | In |
Put | FULC250620P00003000 | 3 | 3.0 | 0.5 - 0.7 | 0.27 | Out |
Put | FULC250620P00002000 | 0 | 2.0 | 0.0 - 0.4 | 0.4 | |
Put | FULC250620P00001000 | 0 | 1.0 | 0.0 - 0.75 | 0.75 |
Fulcrum Total Stockholder Equity
Total Stockholder Equity |
|
Fulcrum Therapeutics Corporate Management
| Rudolf MD | Founder | Profile | |
| CPA CMA | Chief Officer | Profile | |
| Jeffrey Jacobs | Chief Officer | Profile | |
| Mel Hayes | Executive Experience | Profile | |
| Paul Bruno | Senior Development | Profile | |
| Bryan Stuart | CEO Pres | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.16) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.